Joel Barrish

Passionate about Drug Discovery and having an impact on patients in need. Cofounder & CSO at Jnana Tx

[No Patient Left Behind @NPLB_org]

Autoimmune diseases afflict 45 million Americans—and it requires a collective community effort to change that.

@NPLB_org's Community Quest video shows how investors, innovators, regulators, patients, insurers—and you—make new treatments possible, accessible, and affordable.

[Giulio Superti-Furga @giuliosf]

Finally! It is happening! After 6 years of hard work by formidable teams in 13 institutions @RESOLUTE_IMI, we have ordered and validated the results and are able to share the FOUR (4) papers aimed at assigning functional properties to each human SLC #membranetransporter

[No Patient Left Behind @NPLB_org]

45 MILLION Americans suffer from autoimmune diseases—and instead of helping, some health plans make it WORSE. 💥 People pay their premiums, then get slapped with sky-high out-of-pocket costs for their prescription meds. 😡

This is unacceptable. If you or someone you know is fighting an autoimmune disease AND their health plan to get the medicine they need, here’s a simple way to help:

Ask if your employer offers first-dollar coverage for prescribed medicines - and if not, why not? 💔

Stand up and help #FixInsurance NOW. 💪

#InsuranceReform #Firstdollarcoverage #OOP
#autoimmune #chronicdisease #lupus #rheumatoidarthritis #scleroderma #Multiplesclerosis #firstdollarcoverage

[No Patient Left Behind @NPLB_org]

You should never have to fight cancer AND your insurance company.

Half of cancer patients abandon treatment when out-of-pocket costs exceed $2,000.

Prescribed medicines, “covered” by an insurer, should be affordable with low or no out-of-pocket cost.

Let’s #FixInsurance

[No Patient Left Behind @NPLB_org]

If you have Type 1 diabetes, insulin keeps you alive. Why do health plans make you “prove” you need it by charging a copay on top of premiums? No Patient Left Behind is working to #FixInsurance & cap high out-of-pocket costs for prescribed medicines. #T1D #diabetes

[No Patient Left Behind @NPLB_org]

It's just not right... why does insurance charge people out-of-pocket for a medicine no one would take if they didn't have to?

We need to cap these costs for patients and #fixinsurance.

Please share and help, @MariahCarey , @jessicaalba, @Eminem, @Pink, @JeromeBettis36!

[Peter Kolchinsky @PeterKolchinsky]

What no one has yet recognized about Biosecurity is that Americans won't care about who invents or doesn't invent new medicines if they don't think they will be able to afford them anyways.

https://t.co/C382oNGHAj

We need pro-AFFORDABLE innovation policy, not just pro-innovation policy, which means capping what insurance can patients in charge out of pocket costs. What's the point of charging a copay for chemo? Who over-utilizes that? Like if the copay were zero, what reasonable thinks people will fake cancer to joyride chemo?

Unfortunately, many Democrats are still pushing price controls. With the election approaching, listen to how they will keep pounding on the idea pricing all drugs 9 years after launch... or 5 years... or right off the bat. Sure, maybe they want to protect the US biomedical innovation ecosystem from China, but only so that they can undermine it themselves with price controls and show voters ("I did that!"). These politicians will cynically sell out Americans' biomedical future for their votes today.

A small, smart group of Democrats and many Republicans understand that innovation is driven by patent-lengths of market-based rewards, not government price controls. They are wisely proposing a 9-13 fix to the IRA to make sure that all drugs get up to 13 years of their patent life (which averages 14 year normally) after launch. That fix is essential to restore incentives for small molecules of diseases of aging and align with the pro-US-innovation intent of the Biosecurity Act.

@IAmBiotech @PhRMA @NPLB_org

[Joel Barrish @jcbarrish]

@PMashikian @jnanatx @AcsMedi Thanks Paul!

[Joel Barrish @jcbarrish]

@DMHuryn @Roche So awesome to come full circle and now share this honor with @DMHuryn! I just hope that like me it was so long ago that she’s forgotten most of our conversations in the car…

[Jnana Therapeutics @jnanatx]

On #RareDiseaseDay, we’re spotlighting PKU, a rare genetic metabolic disease in which high levels of phenylalanine accumulate in the blood, which can result in neurological impairment & neuropsychological complications. Read about our clinical candidate: https://t.co/yvgxEj04AB

[Joel Barrish @jcbarrish]

Congratulations to the @jnanatx team for their outstanding work leading to the FIH with JNT-517. We’re thrilled to have Bain Capital join Jnana’s Board and are looking forward to working with them to continue to advance Jnana.

[Jnana Therapeutics @jnanatx]

Jnana is thrilled to announce a $107M Series C financing and initiation of our Phase 1 clinical trial in #PKU. The financing will support the PKU program and our preclinical programs in immune-mediated diseases and cancer. Learn more: https://t.co/DVX1wmb4es #BiotechNews

[Joel Barrish @jcbarrish]

Outstanding work by the @jnanatx team! Very excited by the potential of JNT-517 for PKU patients. #PKU

[Joanne Kotz @JoanneKotz]

We are thrilled to be able to share data on our lead program with the PKU community as we head toward entering the clinic later this year.

[Joel Barrish @jcbarrish]

@MarkLautens Very sad - Dave was a giant in the field, both science and as a person. He touched many of us as young scientists who weren’t even in his group. First met him at a Natural Products GRC in 1986, will never forget it - or him.

[Joanne Kotz @JoanneKotz]

What a privilege to work with this amazing group 👇

[Joel Barrish @jcbarrish]

An incredible group of colleagues at @jnanatx! Very proud of the culture created by CEO @JoanneKotz where diversity is so highly valued.

[Jnana Therapeutics @jnanatx]

Celebrating the women of Jnana, today and every day – who are having impact across our organization, from our labs to our C-suite. Together we can all #BreakTheBias.

[Joel Barrish @jcbarrish]

@JoanneKotz & I are outraged and heartbroken by Russia’s invasion of Ukraine. #StandWithUkraine️ until Putin stands down. Representing @jnanatx we also stand with other business leaders in disengaging from Russian Industry & its elites. https://t.co/wf4wrWW4qG

[Joel Barrish @jcbarrish]

Virtually every person on the @jnanatx team had an important impact on this program and Development Candidate. I’m in awe of them and humbled to be part of the group.

[Stuart Schreiber @SchreiberStuart]

A human biology-based drug discovery effort coupled with a powerful binder-based chemoproteomics Platform is paving a path for PKU patients @jnanatx. And structure-guided optimization reveals the novel solutions that arise. Bravo @jcbarrish and team.

[Joel Barrish @jcbarrish]

Welcome John! Fantastic to have you on the @jnanatx leadership team

[Jnana Therapeutics @jnanatx]

John Throup is joining Jnana at a pivotal inflection point - his leadership & expertise will be critical as we advance our lead program for #PKU into clinical dev & progress a promising pipeline of programs for hard-to-drug-targets in immune & oncology. https://t.co/gIkXmY1FIe

[Joel Barrish @jcbarrish]

Looking forward to @JoanneKotz ‘s JPM presentation covering the great progress made by the @jnanatx team!

[Jnana Therapeutics @jnanatx]

Jnana CEO, @JoanneKotz, will be presenting at #JPM22 on our next gen chemoproteomic platform to pursue hard-to-drug targets. Learn more here: https://t.co/OhbkS3PvVE

[Joel Barrish @jcbarrish]

What an awesome team!!

[Joanne Kotz @JoanneKotz]

Very thankful to work with an amazing group of people at Jnana. Happy thanksgiving!